Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.25
RPTP's Cash to Debt is ranked higher than
70% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. RPTP: 1.25 )
RPTP' s 10-Year Cash to Debt Range
Min: 1.25   Max: No Debt
Current: 1.25

Equity to Asset 0.26
RPTP's Equity to Asset is ranked higher than
50% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. RPTP: 0.26 )
RPTP' s 10-Year Equity to Asset Range
Min: -1.88   Max: 0.93
Current: 0.26

-1.88
0.93
F-Score: 4
Z-Score: 2.23
M-Score: -0.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -57.63
RPTP's Operating margin (%) is ranked higher than
53% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.26 vs. RPTP: -57.63 )
RPTP' s 10-Year Operating margin (%) Range
Min: -5100   Max: -57.63
Current: -57.63

-5100
-57.63
Net-margin (%) -75.60
RPTP's Net-margin (%) is ranked higher than
52% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.01 vs. RPTP: -75.60 )
RPTP' s 10-Year Net-margin (%) Range
Min: -5000   Max: -75.6
Current: -75.6

-5000
-75.6
ROE (%) -188.01
RPTP's ROE (%) is ranked lower than
54% of the 894 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. RPTP: -188.01 )
RPTP' s 10-Year ROE (%) Range
Min: -2769.55   Max: -18.3
Current: -188.01

-2769.55
-18.3
ROA (%) -40.57
RPTP's ROA (%) is ranked higher than
52% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.27 vs. RPTP: -40.57 )
RPTP' s 10-Year ROA (%) Range
Min: -158.44   Max: -15.91
Current: -40.57

-158.44
-15.91
ROC (Joel Greenblatt) (%) -778.86
RPTP's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.87 vs. RPTP: -778.86 )
RPTP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -24665.88   Max: -350.25
Current: -778.86

-24665.88
-350.25
EBITDA Growth (3Y)(%) -19.70
RPTP's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. RPTP: -19.70 )
RPTP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -83.1   Max: 91.8
Current: -19.7

-83.1
91.8
EPS Growth (3Y)(%) -10.30
RPTP's EPS Growth (3Y)(%) is ranked higher than
66% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.30 vs. RPTP: -10.30 )
RPTP' s 10-Year EPS Growth (3Y)(%) Range
Min: -86.8   Max: 97
Current: -10.3

-86.8
97
» RPTP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

RPTP Guru Trades in Q4 2013

Paul Tudor Jones 12,049 sh (New)
Steven Cohen 130,800 sh (unchged)
» More
Q1 2014

RPTP Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
» More
Q3 2014

RPTP Guru Trades in Q3 2014

Steven Cohen 418,500 sh (New)
Joel Greenblatt 22,595 sh (New)
» More
Q4 2014

RPTP Guru Trades in Q4 2014

Steven Cohen Sold Out
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RPTP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 15.55
RPTP's P/B is ranked lower than
55% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. RPTP: 15.55 )
RPTP' s 10-Year P/B Range
Min: 0.3   Max: 43
Current: 15.55

0.3
43
P/S 10.78
RPTP's P/S is ranked lower than
51% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.38 vs. RPTP: 10.78 )
RPTP' s 10-Year P/S Range
Min: 0.42   Max: 287.57
Current: 10.78

0.42
287.57
EV-to-EBIT -19.93
RPTP's EV-to-EBIT is ranked higher than
53% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.80 vs. RPTP: -19.93 )
RPTP' s 10-Year EV-to-EBIT Range
Min: -43.6   Max: 129.3
Current: -19.93

-43.6
129.3
Current Ratio 5.89
RPTP's Current Ratio is ranked higher than
89% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. RPTP: 5.89 )
RPTP' s 10-Year Current Ratio Range
Min: 0.59   Max: 13.39
Current: 5.89

0.59
13.39
Quick Ratio 5.58
RPTP's Quick Ratio is ranked higher than
89% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. RPTP: 5.58 )
RPTP' s 10-Year Quick Ratio Range
Min: 0.59   Max: 13.39
Current: 5.58

0.59
13.39
Days Inventory 306.96
RPTP's Days Inventory is ranked higher than
57% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.83 vs. RPTP: 306.96 )
RPTP' s 10-Year Days Inventory Range
Min: 235.18   Max: 331.22
Current: 306.96

235.18
331.22
Days Sales Outstanding 39.15
RPTP's Days Sales Outstanding is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 78.61 vs. RPTP: 39.15 )
RPTP' s 10-Year Days Sales Outstanding Range
Min: 0.78   Max: 1095
Current: 39.15

0.78
1095

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 17.87
RPTP's Price/Tangible Book is ranked lower than
51% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. RPTP: 17.87 )
RPTP' s 10-Year Price/Tangible Book Range
Min: 0.86   Max: 113.5
Current: 17.87

0.86
113.5
Earnings Yield (Greenblatt) -5.00
RPTP's Earnings Yield (Greenblatt) is ranked higher than
53% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. RPTP: -5.00 )
RPTP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 22393.9
Current: -5

0.8
22393.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:XYXR.Germany,
Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. The Company is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The Company's product, PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older. The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine, received marketing authorization on September 6, 2013 from the European Commission, as an orphan medicinal product for the management of proven nephropathic cystinosis for marketing in the European Union. PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of innovative microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Cysteamine is a highly-reactive molecule generated in the cell during the metabolism of cysteine. The Company's pipeline products include; its proprietary delayed-release form of cysteamine, or RP103. The Company currently has product candidates in clinical development designed to potentially treat Huntington's disease, Non-alcoholic fatty liver disease, Leigh syndrome and other mitochondrial disorders and aldehyde dehydrogenase deficiency. The Company's preclinical programs are based upon bioengineered novel drug candidates that are designed to target cancer and other diseases. Its other clinical-stage product candidates include: Convivia its proprietary oral formulation of 4-methylpyrazole, for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2, deficiency, an inherited metabolic disorder. With respect to any of the Company's product candidates for which it obtain FDA approval, it will be subject to ongoing FDA obligations and continued regulatory review, which may result in significant additional expense.
» More Articles for RPTP

Headlines

Articles On GuruFocus.com
My Portfolio Jan 22 2015 
comment on RPTP Mar 16 2013 

More From Other Websites
Raptor Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Mar 11 2015
Raptor Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Mar 11 2015
RAPTOR PHARMACEUTICAL CORP Financials Mar 10 2015
10-K for Raptor Pharmaceutical Corp. Mar 04 2015
Raptor Pharmaceutical to Observe International Rare Disease Day Through Global Awareness Programs Mar 04 2015
RAPTOR PHARMACEUTICAL CORP Files SEC form 10-K, Annual Report Mar 02 2015
Raptor Pharmaceutical reports 4Q loss Feb 26 2015
Raptor Pharmaceutical reports 4Q loss Feb 26 2015
RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 26 2015
Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015... Feb 26 2015
Raptor Pharmaceutical Reports Fourth Quarter and Full Year 2014 Financial Results and Provides 2015... Feb 26 2015
Q4 2014 Raptor Pharmaceutical Corp Earnings Release - After Market Close Feb 26 2015
Wedbush Previews Raptor Pharmaceutical Q4, Lowers Sales Estimates Feb 23 2015
Raptor Pharmaceutical to Observe International Rare Disease Day Through Global Awareness Programs Feb 23 2015
Raptor Pharmaceutical to Attend Upcoming Investor Conferences Feb 18 2015
Raptor Pharmaceutical to Attend Upcoming Investor Conferences Feb 18 2015
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2014 Financial Results Conference Call... Feb 17 2015
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2014 Financial Results Conference Call... Feb 17 2015
RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Shareholder Director Nominations, Other Events Feb 13 2015
PROCYSBI(R) to Receive New Treatment Award From Lysosomal Disease Network at the 11th Annual WORLD... Feb 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK